Biotech industry seeks control of its destiny

Biotech industry seeks control of its destiny
Human Genome Sciences and a small but determined group of its peers are charting unconventional territory. Their efforts to take over the production, sales and marketing of selected portions of their portfolios signals a potential turning point in the industry. The companies contend that they can and should own more of the process that delivers biotechnology’s molecules to market – a process now firmly in the control of the pharmaceutical industry.

Leave a Reply

Your email address will not be published. Required fields are marked *

Get email updates

Enter your email address to subscribe to this blog and receive notifications of new posts by email.